Alternative to Oral Vancomycin for C. difficile Infection
Fidaxomicin 200 mg twice daily for 10 days is the preferred alternative to oral vancomycin for C. difficile infection. 1
Treatment Algorithm Based on Clinical Scenario
Initial CDI Episode
- First-line: Fidaxomicin 200 mg PO twice daily × 10 days 1
- Acceptable alternative: Vancomycin 125 mg PO four times daily × 10 days 1
- Last resort (only for nonsevere CDI if above unavailable): Metronidazole 500 mg PO three times daily × 10-14 days 1
- Nonsevere defined as: WBC ≤15,000 cells/μL AND creatinine <1.5 mg/dL 1
First Recurrence
- Preferred: Fidaxomicin 200 mg twice daily × 10 days, OR extended regimen (twice daily × 5 days, then every other day × 20 days) 1
- Alternative: Vancomycin tapered/pulsed regimen (125 mg four times daily × 10-14 days, then twice daily × 7 days, then daily × 7 days, then every 2-3 days × 2-8 weeks) 1
Second or Subsequent Recurrence
Multiple options exist 1:
- Fidaxomicin (standard or extended regimen)
- Vancomycin tapered/pulsed regimen
- Vancomycin 125 mg four times daily × 10 days followed by rifaximin 400 mg three times daily × 20 days
- Fecal microbiota transplantation (after ≥2 recurrences, meaning 3 total CDI episodes) 1
Fulminant CDI
- High-dose vancomycin 500 mg PO/NG four times daily 1
- PLUS IV metronidazole 500 mg every 8 hours 1
- PLUS rectal vancomycin 500 mg every 6 hours if ileus present 1
Why Fidaxomicin Over Vancomycin?
Fidaxomicin demonstrates superior outcomes in preventing recurrence. Meta-analyses show fidaxomicin reduces recurrence risk by 31% compared to vancomycin (RR 0.69; 95% CI 0.52-0.91) 2 and achieves 18% higher global cure rates 3. The recurrence rate with fidaxomicin is 16.1% versus 25.4% with vancomycin 2.
This advantage holds across multiple clinical scenarios:
- Initial CDI episodes
- First recurrent CDI
- Both nonsevere and severe CDI
- Inpatient and outpatient settings 2
Clinical cure rates are comparable between the two agents, but fidaxomicin's narrower spectrum and lower recurrence rates make it the preferred choice 4.
Critical Caveats
Cost and availability often dictate real-world practice. The 2021 IDSA/SHEA guidelines acknowledge that fidaxomicin implementation "depends upon available resources" and that "vancomycin remains an acceptable alternative" 1. In many settings, vancomycin continues as the workhorse therapy 5.
Metronidazole should NOT be used except as a last resort for nonsevere CDI when fidaxomicin and vancomycin are unavailable 1, or as adjunctive IV therapy in fulminant disease 1. It is explicitly not recommended as monotherapy in current guidelines 4.
Adjunctive Therapies
Bezlotoxumab (10 mg/kg IV once) can be added during antibiotic treatment for first or subsequent recurrences to reduce future recurrence risk 1. Use caution in patients with congestive heart failure, and note that data combined with fidaxomicin are limited 1.
Common Pitfalls to Avoid
- Do NOT use cholestyramine or bile acid-binding agents concurrently with oral vancomycin or fidaxomicin 4
- Do NOT perform routine test of cure after treatment completion; only retest if symptoms persist or worsen 4
- Do NOT use probiotics for CDI prevention or treatment 4, 6
- Parenteral vancomycin is NOT effective for CDI—only oral formulations work 7